atrasentan has been researched along with Cardiomyopathy, Congestive in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyoshi, K; Eshiro, K; Hayashi, T; Ieshima, M; Kitaura, Y; Matsumura, Y; Mori, T; Nishida, M; Okada, Y; Takaoka, M; Yoshikawa, J; Yoshiyama, M | 1 |
| Al-Khoury, J; Bkaily, G; Chahine, M; D'Orléans-Juste, P; Jacques, D | 1 |
2 other study(ies) available for atrasentan and Cardiomyopathy, Congestive
| Article | Year |
|---|---|
Selective endothelin ET(B) receptor antagonist improves left ventricular function but exaggerates degeneration of cardiomyocytes in J2N-k hamsters.
Topics: Animals; Atrasentan; Cardiomyopathy, Dilated; Cricetinae; Disease Models, Animal; Endothelin B Receptor Antagonists; Heart; Heart Function Tests; Male; Muscle Cells; Myocardium; Pyrrolidines; Ventricular Function, Left | 2005 |
ETB receptor dependent alteration in aortic responses to ET-1 in the cardiomyopathic hamster.
Topics: Animals; Aorta; Atrasentan; Cardiomyopathy, Dilated; Cricetinae; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Endothelium, Vascular; In Vitro Techniques; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Vasoconstriction | 2006 |